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Cancer in Iowa
In 2013, an estimated 6,400 Iowans will die from cancer, 17 times  
the number caused by auto fatalities. Cancer and heart disease are  
the leading causes of death in Iowa. These projections are based upon  
mortality data the State Health Registry of Iowa receives from the Iowa 
Department of Public Health. The Registry has been recording the  
occurrence of cancer in Iowa since 1973, and is one of fourteen  
population-based registries and three supplementary registries  
nationwide providing data to the National Cancer Institute. With 2013 
Cancer in Iowa the Registry makes a general report to the public on  
the status of cancer. This report will focus on:
 
• a description of the Registry and its goals;
• cancer estimates for 2013;
• a special section on breast cancer;
• brief summaries of recent/ongoing research projects;
• a selected list of publications from 2012.
The State Health Registry of Iowa  
C
ancer is a reportable  
disease as stated in the  
Iowa Administrative Code. 
Cancer data are collected by 
the State Health Registry of Iowa, 
located at The University of Iowa 
in the College of Public Health’s 
Department of Epidemiology.  
The staff includes more than 50 
people. Half of them, situated 
throughout the state, regularly 
visit hospitals, clinics, and medical 
laboratories in Iowa and neighbor-
ing states to collect cancer data. 
Hospital cancer programs approved 
by the American College of  
Surgeons also report their data.  
A follow-up program tracks more 
than 99 percent of the cancer 
survivors diagnosed since 1973. 
This program provides regular 
updates for follow-up and survival. 
The Registry maintains the 
confidentiality of the patients, 
physicians, and hospitals  
providing data. 
In 2013 data will be collected on 
an estimated 17,300 new cancers 
among Iowa residents. In situ cases 
of bladder cancer are included in the 
estimates for bladder cancer, to be 
in agreement with the definition of 
reportable cases of the Surveillance, 
Epidemiology, and End Results 
(SEER) Program of the National 
Cancer Institute. 
Since 1973 the Iowa Registry  
has been funded by the SEER 
Program of the National Cancer 
Institute. Iowa represents rural 
and Midwestern populations and 
provides data included in many NCI 
publications. Beginning in 1990 
about 5-10 percent of the Registry’s 
annual operating budget has been 
provided by the state of Iowa. 
Starting in 2003, the University 
of Iowa has also been providing 
cost-sharing funds. In addition the 
Registry receives funding through 
grants and contracts with university, 
state, and national researchers 
investigating cancer-related topics. 
The State Health Registry of Iowa is the best statewide resource for determining the burden  
of cancer on the Iowa population and assessing trends in the occurrence of cancer over time.  
The goals of the Registry are to:
•  assemble and report measure- 
ments of cancer incidence, survival  
and mortality among Iowans;
•	 provide information on  
changes over time in the  
extent of disease at diagnosis,  
therapy, and patient survival;
•  promote and conduct studies  
designed to identify factors  
relating to cancer etiology,  
prevention and control; 
•  respond to requests from  
individuals and organizations  
in the state of Iowa for cancer  
data and analyses; 
•  provide data and expertise for  
cancer research activities and  
educational opportunities. 
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Cancer Projections for 2013
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Projected Number of Cancer Deaths in Iowa for 2013
Projected Number of New Cancers in Iowa for 2013
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NEW CANCERS IN FEMALES
Type	 #	of	Cancers	 %	of	Total
Breast 2300 27.4
Lung 1000 11.9
Colon & Rectum 800 9.5
Uterus 650 7.7
Skin Melanoma 380 4.5
Non-Hodgkin Lymphoma 370 4.4
Thyroid 300 3.6
Ovary 240 2.9
Leukemia 230 2.7
Kidney & Renal Pelvis 210 2.5
All Others 1920 22.9
Total	 8400
NEW CANCERS IN MALES
Type	 #	of	Cancers	 %	of	Total
Prostate 2200 24.7
Lung 1300 14.6
Colon & Rectum 840 9.4
Bladder  
(invasive and noninvasive) 630 7.1
Skin Melanoma 460 5.2
Non-Hodgkin Lymphoma 430 4.8
Kidney & Renal Pelvis 390 4.4
Leukemia 290 3.3
Oral Cavity 260 2.9
Pancreas 240 2.7
All Others 1860 20.9
Total	 8900
CANCER DEATHS IN FEMALES
Type	 #	of	Cancers	 %	of	Total
Lung 710 23.7
Breast 410 13.7
Colon & Rectum 320 10.7
Pancreas 200 6.7
Ovary 180 6.0
Non-Hodgkin Lymphoma 120 4.0
Leukemia 120 4.0
Uterus 110 3.6
Brain 70 2.3
Kidney & Renal Pelvis 60 2.0
All Others 700 23.3
Total	 3000
CANCER DEATHS IN MALES
Type	 #	of	Cancers	 %	of	Total
Lung 990 29.1
Colon & Rectum 330 9.7
Prostate 320 9.4
Pancreas 200 5.9
Leukemia 150 4.4
Esophagus 140 4.1
Non-Hodgkin Lymphoma 140 4.1
Bladder 120 3.5
Kidney & Renal Pelvis 110 3.2
Liver 100 3.0
All Others 800 23.6
Total	 3400
Fortunately for Iowans, the chances of being diagnosed with many types of cancer can be reduced through positive health 
practices such as smoking cessation, physical exercise, healthful dietary habits, and alcohol consumption in moderation.  
Early detection through self-examination and regular health checkups can improve cancer survival.  
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Top 10 Types of Cancer in Iowa Estimated for 2013
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Breast Cancer in Iowa Women
Breast cancer is the most 
commonly registered cancer among 
women in Iowa. Today, there are 
over 33,000 women in Iowa living 
with a diagnosis of breast cancer. 
Between 1976 and 2010, there 
were 79,092 newly diagnosed  
in situ (confined to the lobular 
or ductal lining of the breast) 
and invasive breast cancers. Age-
adjusted invasive female breast 
cancer incidence (new cases) rates 
during this 35-year period were 
stable from 1976 to 1982, rose 
steeply from 1983 through 1988, 
were stable from 1989 to 1998, 
and declined slightly from 1999 to 
2010 (Figure 1). Breast cancer can 
also occur in men, but data show it 
is 150 times less likely as there are 
less than 20 cases per year in Iowa.  
Breast cancer has been the 
underlying cause of death for 
17,089 Iowa women between 1976 
and 2010. Age-adjusted breast 
cancer mortality rates were stable 
from 1976 to 1992, then decreased 
an appreciable 40% through 2010 
(Figure 2). The 2010 rate of 19.4 
approached the goal of 19.0 set 
several years prior in the statewide 
plan to improve the health of 
Iowans, called Healthy Iowans 2010. 
Demographic differences exist for 
females regarding both incidence 
and mortality rates. Increasing 
age is a very strong risk factor 
for both breast cancer incidence 
and mortality. Over 72% of these 
cancers diagnosed between 1976 
and 2010 occurred in women 
age 55 years and older; only 10% 
were diagnosed in women less 
than 45 years of age. For women 
dying from breast cancer during 
this same time period, 82% of 
these deaths occurred in women 
age 55 years and older, while only 
6% occurred in women less than 
45 years of age. Rural counties 
compared to urban counties in 
Iowa have both slightly lower age-
adjusted incidence and mortality 
rates for female breast cancer. 
Similar to the national experience, 
Whites compared to Blacks in 
Iowa have a slightly higher age-
adjusted incidence rate for female 
breast cancer, but Blacks have a 
higher age-adjusted mortality rate. 
Over the 35-year period, these 
relationships with age, urban/rural 
counties, and race have persisted 
with the exception of urban/rural 
counties where during  the 2000-
2010 period the female mortality 
rates in rural counties caught up to 
the urban counties’ rates.   
Most breast cancer risk factors 
reflect a woman’s lifetime expo-
sure to estrogen and possibly 
progesterone. These factors include 
early age at first menses, late age 
at menopause, having no children 
or having a first birth at a later 
age, lack of or short-term breast 
feeding, obesity after menopause, 
long-term use of hormone 
Figure 1.  Annual in situ and invasive breast cancer incidence rates, Iowa, 1976-2010
 (Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population)
RATE
YEAR	OF	DIAGNOSIS
Invasive          In situ
7replacement therapy, and alcohol 
intake of at least one drink per day. 
The most important breast cancer 
risk factor is genetic predisposition 
often reflected in first-degree 
relatives (mother, sister, daughter) 
who have been diagnosed with 
breast cancer or ovarian cancer. 
This is likely due to inherited 
genes, the most established of 
which are BRCA1 and BRCA2. High 
mammographic breast density 
and radiation exposure are other 
established, important risk factors.  
Breast cancer control centers on 
women getting mammograms.  
The American Cancer Society 
currently recommends that women 
in the general population begin 
obtaining an annual mammogram 
and clinical breast exam at age  
40 years. Women with genetic 
predisposition should pursue 
annual breast cancer screening 
tests for early detection even 
before the age of 40. Through 
these early detection tests, breast 
cancers can be detected while still 
confined to the lobular or ductal 
lining of the breast tissue from 
which they arise, so called in situ 
breast cancers. The annual rates of 
this behavior of breast cancer have 
increased 6-fold in Iowa since 1984, 
as shown in Figure 1, and are 
directly attributable to the increas-
ing utilization of mammography, 
the single most effective method 
of early detection. In 2010, based 
on Behavioral Risk Factor Surveil-
lance System data, there remain an 
estimated 24% of Iowa women age 
40 years and older reporting not 
having had a mammogram in the 
past two years. This percent has 
changed little since the year 2000. 
This percent also varies by age 
group and even more strongly 
varies by education with over 40% 
of women with less than high 
school education reporting not 
having had a mammogram in the 
past two years (Figure 3). Annual 
screening is successful because 
there are effective treatment 
options for early stage breast 
cancer that prolong survival, 
thereby decreasing the rate of 
breast cancer deaths. 
One of the keys to reducing  
death from breast cancer is to 
detect it at an early stage. At time 
of diagnosis, early stage breast 
cancers are those confined to  
the breast, whereas late stage 
breast cancers have spread beyond 
the breast. As can be seen in  
Figure 4, 7 out of every ten  
newly diagnosed breast cancers 
have been early stage since the 
1991 to 1995 period. This compares 
with only 5 out of every ten  
being early stage in the 1976 to 
1985 periods. In 2010, the 28% 
with late stage disease is similar  
to the 24% reporting not having 
had a mammogram in the past 
two years.    
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Figure 2.  Annual breast cancer mortality rates, Iowa, 1976-2010
 (Rates are per 100,000 and are age-adjusted to 2000 U.S. standard population)
RATE
YEAR	OF	DIAGNOSIS
8Survival rates for breast cancer 
have been increasing. For women 
diagnosed with breast cancer in 
2001-2005, the 5-year relative 
survival rate was 100% for early 
stage disease and 77% for late 
stage disease (Figure 5). Late stage 
disease includes as a subgroup 
women who had spread of their 
breast cancer to distant organs 
at the time of diagnosis. This 
subgroup’s 5-year relative survival 
rate was 29%. Fortunately, this 
subgroup comprises only 4% of all 
breast cancers diagnosed during 
2001-2005. Early detection via 
mammography and improved 
treatment have been reported as 
the factors most responsible for 
the increasing female breast  
cancer survival rates.    
Today, molecular subtyping of 
breast cancer tissue is used in 
planning treatment and devel-
oping new therapies. There are 
four major molecular subtypes 
determined by using molecular  
and genetic information from 
breast cancer cells. Hormone 
receptor status and Her2/neu 
status are molecular markers 
measured to assist in determining 
these subtypes (Table 1). For 1,523 
female invasive breast cancers 
newly diagnosed in 2010 in Iowa, 
the luminal A subtype was the 
Figure 4. Frequency distribution of female breast cancer by stage, Iowa, 1976-2010
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most frequent. The other three 
subtypes were far less frequent 
and led by the triple negative 
subtype. The percent distribution 
of these subtypes varied by age 
at diagnosis with triple negative 
having its highest percent under 
age 45 years at diagnosis, whereas 
luminal A always had the largest 
percent in any age group but this 
percent increased with increasing 
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Figure 3. Percent of Iowa female population in 2010 who reported
 NOT having a mammogram within the past two years
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Figure 5. Relative 5-year survival percents for female breast cancer, Iowa, 1976-2005
age. The Iowa data are consistent 
with the White race data for the 
entire United States. 
Prognosis and treatment 
decisions are guided by tumor 
stage, hormone receptor status, 
and HER2/neu status. Triple 
negative tumors are usually 
treated with some combination 
of surgery, radiation therapy and 
chemotherapy. These tumors 
cannot be treated with hormone 
therapies because the tumor cells, 
being hormone receptor negative, 
do not respond to such therapies. 
The other three tumor subtypes 
can all include hormone therapies 
in their treatment regimens. 
Luminal A cancers tend to have 
the best survival; triple negative 
cancers have the poorest survival.
Table 1. Frequency distribution of molecular subtypes for breast cancer   
 cells in Iowa females with newly diagnosed invasive breast 
 cancer in 2010, all ages
Subtype Markers* Number Percent
Luminal A ER+ and/or PR+, HER2- 1,133 74.4
Luminal B ER+ and/or PR+, HER2+ 136 8.9
HER2/neu ER-, PR-, HER2+ 75 4.9
Triple negative ER-, PR-, HER2- 179 11.8
Total* 1,523 100.0
ER+ = estrogen receptor-positive; ER- = estrogen receptor-negative; PR+ = progesterone 
receptor-positive; PR- = progesterone receptor-negative; HER2+ = HER2/neu-positive; 
HER2- = HER2/neu-negative
*Includes only those breast cancers that had markers measured to allow  
subtype classification; 824 of the 2,347 (35%) invasive breast cancers  
diagnosed in 2010 were not classifiable
Early Stage         Late Stage   PERCENT
YEARS	OF	DIAGNOSIS
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Research Projects During 2013
The State Health Registry of Iowa 
is participating in over 60 studies 
approved by the University of Iowa 
Human Subjects Office during 2013. 
Brief descriptions of a few of these 
studies are provided.
AGRICULTURAL HEALTH STUDY
The Agricultural Health Study 
(AHS) is a long-term study of 
agricultural exposures (including 
pesticides) and chronic disease 
(especially cancer) among 
commercial or private pesticide 
applicators (and their spouses, 
if married) in Iowa and North 
Carolina. The study is funded 
through the National Cancer 
Institute and involves several 
federal agencies. We are in the 
21st year of the study. 
In the first five years, 89,658 
subjects (58,564 in Iowa and 
31,094 in North Carolina) were 
enrolled in the study. The total 
for Iowa included 31,877 private 
applicators, 21,771 spouses 
of private applicators, and 
4,916 commercial applicators. 
Enrollment consisted of completing 
questionnaires about past 
exposures and health. The second 
phase of the study for private 
applicators and their spouses was 
completed at the end of 2003. It 
involved a telephone interview, 
a mailed dietary questionnaire, 
and collection of a cheek cell 
sample from all consenting cohort 
members. The telephone interview 
asked about pesticide use since 
enrollment, current farming and 
work practices, and health changes. 
The dietary health questionnaire 
asked about cooking practices and 
types of foods eaten, since cooking 
practices and diet may play a 
role in cancer and other health 
conditions. The cheek cells are 
being used to understand possible 
links between genetics, exposures, 
and disease. For commercial 
applicators, the second phase of 
the study was completed at the 
end of 2005. The study’s third 
phase began in 2005 and ended 
in 2010. It involved updating 
information about exposures and 
health. The fourth phase of the 
study began in the fall of 2011 and 
for the University of Iowa research 
team primarily involves collection 
of blood and urine samples from 
a select subgroup of AHS male 
participants and collection of 
buccal cells from AHS participants 
diagnosed with cancer.      
Since 1997, cohort members 
have been linked annually to 
mortality and cancer registry 
incidence databases in both states. 
In addition, mortality data on the 
cohort are being obtained from 
the National Death Index. More 
information about results from 
this study, the study background, 
frequently asked questions, other 
resources (internet & telephone) 
for agricultural health information, 
references for publications to 
date, and information for scientific 
collaborators can be found at 
the website, http://aghealth.
nci.nih.gov/. The titles for over 
175 publications from this study 
linked to PubMed are available at 
the website. The cancer-related 
references for 2012 publications 
are provided in the last section of 
this report.
IOWA WOMEN’S HEALTH STUDY
This is a population-based cohort 
of 41,837 Iowa women, aged 55-
69, who were recruited in 1986 to 
determine whether diet, body fat 
distribution and other risk factors 
are related to cancer incidence. 
Exposure and lifestyle information 
was collected in a baseline mailed 
survey and subsequently in several 
follow-up mailed surveys. Mortality 
and cancer incidence have been 
ascertained since 1986 through 
annual linkage to the State Health 
Registry of Iowa databases and 
the National Death Index. In 2010 
the study was funded for years 
25-29. This study’s data have 
also been pooled with data from 
other cohort studies and analyzed 
as international collaborative 
activities. Over time, this has 
led to over 240 cancer-related 
publications, some of which 
occurred in 2012 and are listed  
in the references provided in the 
last section of this report. 
NON-HODGKIN LYMPHOMA 
(NHL) CASE-CONTROL STUDY
The State Health Registry of Iowa 
(SHRI) with other investigators at 
the Mayo Clinic participated in a 
collaborative, population-based 
case-control study of NHL involving 
researchers at the National 
Cancer Institute and three other 
Surveillance, Epidemiology, and End 
Results (SEER) registries. The main 
objective of the study was to better 
characterize risk factors for NHL. 
In Iowa, 364 live patients newly 
diagnosed with NHL between July 
1, 1998 and June 30, 2000 were 
11
enrolled. A similar number of 
population controls participated. 
Blood samples were sought from 
study participants. The SHRI also 
coordinated the acquisition of 
pathology reports, slides and 
tissue blocks from all SEER centers. 
The slides were reviewed to 
determine the reliability of NHL 
pathologic classification. More 
recently, we are collaborating 
with researchers to investigate 
whether genes with functional, 
common variant polymorphisms 
involved in immune function and 
regulation are associated with 
overall survival from NHL among 
these patients. To achieve this 
aim, medical record reviews were 
performed to obtain more detailed 
information on the treatment 
received for NHL. This study’s 
data have also been pooled with 
data from other NHL case-control 
studies and analyzed as part of the 
InterLymph Consortium, a group 
of international investigators who 
discuss and undertake research 
activities with these data. All of 
these research activities resulted 
in several publications during 
2012. The references for these are 
provided in the last section of  
this report. 
PATTERNS OF CARE STUDIES
SEER Patterns of Care Studies 
are conducted to satisfy a U.S. 
Congressional directive to the 
National Cancer Institute to 
“assess the incorporation of 
state-of-the-art cancer treatment 
into clinical practice and the 
extent to which cancer patients 
receive such treatments.” This 
year’s Patterns of Care Study will 
involve mesothelioma, ovarian, 
and metastatic melanoma cancers 
in adults and brain cancers 
in both children and adults 
diagnosed between January 1, 
2011 and December 31, 2011. 
Neuroblastoma cancers will also 
be included in both children and 
adults diagnosed between January 
1, 2010 and December 31, 2011. 
The objectives of the SEER Patterns 
of Care Study are to: 1) describe 
the use of adjuvant therapy, 
which has been verified with the 
treating physician, in a community 
setting, 2) characterize the practice 
patterns in different communities, 
3) describe more completely the 
use of surgery in the treatment  
of specific cancers, 4) compare the 
patterns of treatment for cancer 
over time, 5) compare patterns 
of care by age and race/ethnicity, 
6) describe effect of co-morbid 
conditions on treatment, and  
7) describe treatment by hospital 
characteristics: i.e. for profit vs. 
not for profit, teaching vs. non-
teaching, disproportionate share 
status, etc. The SHRI has been 
involved with these types of 
studies over the past 20 years. 
Publications during 2012 are 
provided in the last section of  
this report. 
AYA HOPE STUDY
The Adolescent and Young 
Adult (AYA) Health Outcomes and 
Patient Experience (HOPE) Study 
is another ongoing example of a 
cancer survivor study. This study 
is an initial step in addressing 
potential factors related to gaps 
in research, care and outcomes. 
From 7 SEER Registries across 
the United States, 525 patients 
(40 in Iowa), 15-39 years old at 
diagnosis between July 1, 2007 
and October 31, 2008 have been 
enrolled with any of the following 
cancers:  ovarian or testicular 
cancer, Hodgkin lymphoma, 
non-Hodgkin lymphoma, acute 
lymphoblastic leukemia, or 
selected types of sarcoma. 
Those who responded were 
representative of all AYA cancer 
survivors during this time period. 
91% of the 525 have completed a 
subsequent survey 8 to 17 months 
after the initial survey to obtain 
additional follow-up information 
regarding their cancer survivorship 
experience. During 2012, additional 
publications have reported findings 
from this study and are provided in 
the last section of this report. 
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STUDIES INVOLVING TISSUE
Today, researchers are increasingly 
looking to obtain tissue to study 
molecular characteristics of 
cancers. Several studies that 
involve the State Health Registry  
of Iowa have included tissue. 
During 2012, several articles 
involving tissue from Iowans  
were published, the references  
for which are provided in the  
last section of this report.      
THE WECARE STUDY
The WECARE (Women’s 
Environmental Cancer and 
Radiation Epidemiology) Study is 
an example of a second cancer 
study. This study is designed 
to examine gene carrier status, 
demographic and lifestyle factors, 
as well as environmental and 
treatment factors reported to be 
associated with an initial breast 
cancer as they relate to the 
development of a second breast 
cancer in the opposite breast. 
Eligible cases were diagnosed 
with a first breast cancer between 
1985 and 2009 that did not 
spread beyond the regional lymph 
nodes at diagnosis and a second 
primary contralateral breast 
cancer diagnosed at least one 
year after the first breast cancer 
diagnosis. Eligible controls were 
women with unilateral breast 
cancer who were individually 
matched to cases on year of birth, 
year of diagnosis, registry region, 
and race. The controls must have 
survived without any subsequent 
diagnosis of cancer and with an 
intact contralateral breast during 
the interval that elapsed between 
their matched case’s first and 
second breast cancer diagnoses. 
Data collection not only involved 
medical record review, but also 
participant interviews and 
biosample collection, either cheek 
cells or blood. The WECARE staff 
will be collecting mammographic 
film data for its research subjects 
in 2013 and 2014 to evaluate 
breast density as a risk factor for a 
subsequent diagnosis of invasive 
breast cancer in the contralateral 
breast. A listing of publications 
from the WECARE Study during 
2012 are provided in the last 
section of this report.
SEER-MEDICARE
In the early 1990s, the cancer 
incidence and survival data from 
the State Health Registry of 
Iowa was combined with other 
SEER Registry data and linked 
to Medicare data. This linked 
data set has been updated on 
several occasions since and 
has become an important data 
resource for cancer research 
involving epidemiologic and 
health services research related 
to the diagnosis and treatment 
procedures, costs, and survival of 
cancer patients. Over the years 
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listed at http://healthservices.
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publications.html. 
COOPERATIVE AGREEMENTS 
AND OTHER REGISTRIES
In the Midwest, the SHRI 
maintains cooperative agreements 
with several hospital cancer 
registries and other agencies/
entities. Some of the latter include:
n  Iowa Department of  
  Public Health
n  Iowa Cancer Consortium 
n  The University of Iowa
 • Center for Health Effects of  
   Environmental Contamination
 • Center for Health Policy and  
   Research
 • Center for Public Health   
   Statistics
 • Environmental Health   
   Sciences Research Center
 • Health Effectiveness Research  
   Center
 • Holden Comprehensive  
   Cancer Center
 • Iowa Center for Agricultural  
   Safety and Health
 • Iowa Center for Education   
   and Research on Therapeutics  
   (Iowa CERT)
 • Injury Prevention Research   
   Center
 • Nutrition Center
 • Preventive Intervention   
   Center 
 • Reproductive Molecular   
   Epidemiology Research &   
   Education Program
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